Sunday, July 27, 2025 1:19:02 PM
Critics of the "Winterfell" analysis may say, "how could such a bold and expensive undertaking, if it has direct relevance to NWBO, not have included signed agreements?" That's a fair question assuming a conventional strategy was followed, but I see another rationale, which could explain why it wasn't necessary.
When LP was asked about a B0 or partnership during an ASM a few years back, she didn't hesitate to say, 'NWBO needs more than just a checkbook." She clearly knew, as have longs, that NWBO had the leverage, and that leverage has grown exponentially, year after year, since then. She also said, nothing is off the table, "if she is given an offer she couldn't refuse." Naturally, one would assume, she meant a check so big, that mere mortals couldn't tear themselves away from it.
In comes "Winterfell to demonstrate all things NWBO is not financially or structurally leveraged to remotely consider, as a model it could replicate, let alone its massive scalability, and immediacy.
Longs kept asking, why would a company like Merck not do a deal immediately, and take a risk by waiting? "Winterfell" appears to have answered that question. IMHO.
When LP was asked about a B0 or partnership during an ASM a few years back, she didn't hesitate to say, 'NWBO needs more than just a checkbook." She clearly knew, as have longs, that NWBO had the leverage, and that leverage has grown exponentially, year after year, since then. She also said, nothing is off the table, "if she is given an offer she couldn't refuse." Naturally, one would assume, she meant a check so big, that mere mortals couldn't tear themselves away from it.
In comes "Winterfell to demonstrate all things NWBO is not financially or structurally leveraged to remotely consider, as a model it could replicate, let alone its massive scalability, and immediacy.
Longs kept asking, why would a company like Merck not do a deal immediately, and take a risk by waiting? "Winterfell" appears to have answered that question. IMHO.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
